New GLP-1 drugs in development
9 medicines here are still in development and none has FDA approval, so none can be bought as an approved medicine. 7 have Phase 3 trials registered. Nobody outside the companies and FDA can give an approval date, so this page shows what the registry lists: which trials have finished and when the rest are due to.
Trial status and dates read every day from ClinicalTrials.gov, as each sponsor states them. Sponsors change these dates.
Where each one stands
| Medicine | Maker | Stage | Phase 3: finished | Still running | Next due to finish | Last due to finish | Reported weight change |
|---|---|---|---|---|---|---|---|
| MariTide | Amgen | Phase 3 | 0 | 11 | April 2027 | September 2030 | -16.2% at 52 wks |
| Retatrutide | Eli Lilly | Phase 3 | 5 | 6 | November 2026 | February 2029 | -28.3% at 80 wks |
| Survodutide | Boehringer Ingelheim / Zealand Pharma | Phase 3 | 6 | 5 | May 2028 | December 2031 | -16.6% at 76 wks |
| Mazdutide | Eli Lilly / Innovent Biologics | Approved in China; not FDA-filed | 2 | 5 | April 2027 | August 2029 | None reported here |
| VK2735 | Viking Therapeutics | Phase 3 | 0 | 4 | August 2027 | December 2028 | None reported here |
| Aleniglipron | Structure Therapeutics | Phase 3 | 0 | 2 | November 2028 | November 2028 | None reported here |
| Pemvidutide | Altimmune | Phase 3 | 0 | 1 | December 2032 | December 2032 | None reported here |
| Amycretin | Novo Nordisk | Phase 3 | 0 | 0 | None listed | None listed | -24.3% at 36 wks |
| CagriSema | Novo Nordisk | FDA review | 0 | 0 | None listed | None listed | -22.7% at 68 wks |
A trial can search under more than one medicine, for instance when one is the comparator. Weight figures come from separate trials of different lengths and are not a comparison: each medicine's page cites its source.
Can you buy them?
Not as approved medicines. FDA says: “Retatrutide and cagrilintide cannot be used in compounding under federal law.” It adds that they are not components of FDA-approved drugs and have not been found safe and effective for any condition. FDA's page 21 of its warning letters since 2024 mention retatrutide. Read them here.
New GLP-1s: common questions
What new GLP-1 drugs are coming?
9 medicines here are still in development, 7 with Phase 3 trials registered: MariTide, Retatrutide, Survodutide, Mazdutide, VK2735, Aleniglipron, Pemvidutide. None has FDA approval yet.
When will retatrutide be FDA approved?
FDA has not approved retatrutide, and no public record gives an approval date. It is at this stage: Phase 3. The trial registry lists 11 Phase 3 trials: 5 finished and 6 still running. The sponsor lists the last of those as finishing by February 2029, though a company can file with FDA before every trial ends.
Can you buy retatrutide?
No FDA-approved retatrutide exists. FDA says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." It also says these ingredients have not been found safe and effective for any condition. 21 of FDA's warning letters since 2024 mention retatrutide, many to companies selling peptides online. Every FDA warning letter naming a GLP-1